Company:  ALLOGENE THERAPEUTICS, IN ... (ALLO)
Form Type:  S-3ASR
Filing Date:  11/2/2022 
CIK:  0001737287 
Address:  210 EAST GRAND AVENUE 
City, State, Zip:  SOUTH SAN FRANCISCO, California 94080 
Telephone:  (650) 457-2700 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$8.21  
Change: 
0.24 (3.01%)  
Trade Time: 
Feb 02  
Market Cap: 
$1.18B
Trade ALLO now with 

© 2023  
Description of Business
We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell therapies for the treatment of cancer. We are developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient's use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients. Chimeric antigen receptor (CAR) T cell therapy, a form of cancer immunotherapy, has emerged as a revolutionary and potentially curative therapy for patients with hematologic cancers, including refractory cancers.
Register and access this filing in:     
  FORM S-3ASR
    EXPLANATORY NOTE
    TABLE OF CONTENTS
    ABOUT THIS PROSPECTUS
    RISK FACTORS
    SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
    USE OF PROCEEDS
    DESCRIPTION OF CAPITAL STOCK
    Transfer Agent and Registrar
    DESCRIPTION OF DEBT SECURITIES
    DESCRIPTION OF WARRANTS
    PLAN OF DISTRIBUTION
    LEGAL MATTERS
    EXPERTS
    WHERE YOU CAN FIND MORE INFORMATION
    The Offering
    RISK FACTORS
    USE OF PROCEEDS
    DILUTION
    PART II
      Item 14. Other Expenses of Issuance and Distribution.
      Item 15. Indemnification of Officers and Directors.
      Item 16. Exhibits and Financial Statement Schedules
      Item 17. Undertakings
    SIGNATURES
    POWER OF ATTORNEY
  EXHIBIT FILING FEES
  EXHIBIT 1.2
  EXHIBIT 4.7
  EXHIBIT 4.10
  EXHIBIT 4.11
  EXHIBIT 4.12
  EXHIBIT 5.1
  EXHIBIT 23.1
    Consent of Independent Registered Public Accounting Firm


EDGAR® and SEC® are trademarks of the U.S. Securities and Exchange Commission. OTC Markets Group Inc.'s products and services are not affiliated with or approved by the U.S. Securities and Exchange Commission.